Dr. James’ recent work includes representing:
- Teva Pharmaceuticals and Yeda Research and Development, in consolidated Hatch-Waxman litigations concerning proposed generic equivalents to Teva's blockbuster multiple sclerosis drug Copaxone®. Following trial, the court ruled that Teva and Yeda's nine patents in suit were valid, enforceable and infringed by the proposed generic products of defendants Sandoz/Momenta Pharmaceuticals and Mylan/Natco Pharma. Teva Pharmaceuticals USA v. Mylan Pharmaceuticals and Teva Pharmaceuticals USA v. Sandoz (S.D.N.Y.)
- Ben Venue Laboratories in Hatch-Waxman litigation brought by Helsinn and Roche in the District of Delaware on patents concerning the drug product Aloxi® (palonosetron HCl).
- Ben Venue Laboratories in Hatch-Waxman litigation brought by Spectrum Pharmaceuticals in the District of Nevada on patents concerning the drug product Fusilev® (levoleucovorin).
- Teva Pharmaceuticals at trial in the Southern District of New York in a Hatch-Waxman litigation brought by Gilead Sciences on patents concerning the drug product Emtriva® (emtricitabine).
- Intervet in biotechnology patent litigation brought against Intervet's Circumvent® porcine circovirus vaccine. Dr. James represented Intervet at Markman hearing. Intervet obtained a favorable Markman ruling leading to summary judgment of non-infringement and favorable settlement. Intervet v. Merial Limited et al. (D.D.C.)